Feb 11, 2014 02:28 PM
To launch the working year, the Garvan Research Foundation Chairman, Mr Geoff Dixon formally acknowledged the generous support of Garvan’s corporate supporters at an event celebrating outstanding work in the field of employee engagement, Corporate Social Responsibility (CSR) and campaign management.
MEDIA RELEASE: Feb 11, 2014 12:05 AM
Many people suffer from chronic inflammation because their immune systems overreact to ‘self’ tissue. Garvan scientists believe that a small molecule known as Interleukin 21 is a promising therapeutic target in such cases.
MEDIA RELEASE: Feb 05, 2014 04:00 AM
A new study suggests that shivering and bouts of moderate exercise are equally capable of stimulating the conversion of energy-storing ‘white fat’ into energy-burning ‘brown fat’. This makes brown fat a potential therapeutic target against obesity and diabetes.
MEDIA RELEASE: Jan 20, 2014 08:05 AM
Garvan researchers in collaboration with Vietnamese colleagues have now shown that the impact of ‘lean mass’ is 3 times higher than the impact of ‘fat mass’, finally concluding a debate that has lasted for over 20 years.
MEDIA RELEASE: Jan 15, 2014 03:00 AM
The transformation of medicine by human genome sequencing has moved closer following the announcement today that Sydney’s Garvan Institute of Medical Research is one of the first in the world to acquire machines that can sequence a whole human genome at a base cost below $US1,000.
Jan 14, 2014 03:26 PM
Researchers chosen by the NHMRC’s Internal Scientific Planning Group and a Scientific Steering Committee, following public consultation.
MEDIA RELEASE: Jan 08, 2014 04:00 PM
Garvan researchers have shed more light on an underexplored aspect of the important brain-signaling system that controls appetite, body composition and energy use. Their findings suggest that a specific gene regulating our body clock may play a central role in determining how fat we become.
MEDIA RELEASE: Dec 19, 2013 12:00 AM
Garvan is very pleased to announce the appointment of Professor David Thomas as the new Director of The Kinghorn Cancer Centre, as well as Head of Garvan’s Cancer Division, from July 2014. The Kinghorn Cancer Centre is a joint venture of Garvan and St Vincent’s Hospital that brings together the scientific and medical expertise of the two partners to provide a personalised medicine approach to the treatment and care of cancer patients.
MEDIA RELEASE: Dec 19, 2013 12:00 AM
Garvan is very pleased to announce that Professor Neil Watkins will assume the inaugural Petre Foundation Chair of Cancer Biology from January 2014. Professor Watkins is a clinician-scientist who currently holds the positions of Director of the Centre for Cancer Research and Professor of Cancer Biology at Monash University.
MEDIA RELEASE: Dec 04, 2013 04:05 PM
Garvan today announced that it has elected to incorporate Irys technology from BioNano Genomics into its disease research programs, with particular emphasis on improving understanding of prostate cancer. With this purchase, Garvan becomes the first Early Access user of an Irys System in Australia.
MEDIA RELEASE: Nov 30, 2013 12:00 AM
The Garvan Institute and the University of Sydney are proud to announce that from January 2014 Professor Vanessa Hayes will assume the inaugural Petre Foundation Chair of Prostate Cancer Research. Professor Hayes heads the Laboratory for Human Comparative and Prostate Cancer Genomics at Garvan. She also holds a position as Professor of Genomic Medicine at the J. Craig Venter Institute in San Diego, California.
Nov 28, 2013 06:00 PM
Garvan immunologist Dr Daniel Christ has been recognised by the National Health and Medical Research Council (NHMRC) as one of the top-ranked applicants in the 2012 round of grant and fellowship awards. Last night Dr Christ received his Excellence Award at the Academy of Science in Canberra. The award winners represent the top 20 out of 5236 peer reviewed applicants for funding in 2012.
MEDIA RELEASE: Nov 28, 2013 04:05 PM
It is well known that hip and vertebral fractures increase the risk of premature death. Until now, little has been known about the clinical impact of non-hip, non-vertebral fractures – so new Garvan research showing that they may also increase the risk of death will better inform treatment.
Nov 15, 2013 06:00 PM
Dr Angela Chou and Lee Marshall share this year’s $10,000 USD Castle Harlan Award for being the most outstanding early career PhD students at Garvan in 2013. Pathologist Angela Chou has been performing a detailed analysis of two potentially treatable subtypes of pancreatic cancer. Lee Marshall is undertaking a genome-wide study of several regions of the brain that confer susceptibility to Parkinson’s Disease, to find biomarkers that might be used to screen for the disease at an early stage and to identify potential therapeutic targets.
MEDIA RELEASE: Nov 11, 2013 10:00 PM
Garvan scientists have described an exquisitely balanced interplay of four molecules that trigger and govern antibody production in immune cells. As well as being an important basic science discovery, it helps explain why people with mutations in any one of the associated genes cannot fight infection effectively, and develop rare and crippling immunodeficiency disorders.
MEDIA RELEASE: Nov 11, 2013 05:00 PM
While the principle of immune memory has been known for decades, the exact molecular mechanisms underpinning it have remained a mystery. Garvan scientists have now unraveled part of that mystery, identifying the role of a gene called STAT3, which acts as a kind of roundabout, directing chemical messenger molecules to various destinations.
MEDIA RELEASE: Oct 29, 2013 03:05 PM
The pancreas is a large organ that wraps around our gut, and produces the exact amount of insulin our bodies need when we eat – except when we start to develop diabetes, and insulin production slows down. Sydney scientists describe how a fat recycling system within pancreatic ‘beta cells’ determines the amount of insulin they secrete, and so may provide a target for future diabetes therapies.
Oct 25, 2013 04:20 AM
The Garvan Institute received $15.5 million, out of a total funding pool of $559.1 million, in the latest round of National Health and Medical Research Council grants, announced yesterday by Prime Minister Tony Abbott accompanied by federal Minister for Health Peter Dutton. Garvan peformed well, with a success rate of 26% for project grants, well ahead of the national average of 16.9%.
MEDIA RELEASE: Oct 17, 2013 03:05 PM
Scientists from Garvan and CSIRO announced their ‘Molecular Control Toolkit’ at the 3rd IEEE Symposium on Biological Data Visualization in Atlanta, Georgia, USA on Sunday. The toolkit is an innovative piece of software designed to connect commercially available gesture and voice recognition devices with any molecular graphics system, allowing people to control 3D representations of molecules with their hands.
MEDIA RELEASE: Oct 15, 2013 03:05 PM
Clinical researchers from Garvan and St. Vincent’s Hospital have shown that a form of weight loss surgery, known as ‘gastric banding’, brings about reversal of diabetes in some patients, and dramatic improvement of glucose tolerance in others, within 12 weeks.